Viking Therapeutics (VKTX) Gains from Investment Securities: 2015-2025
Historic Gains from Investment Securities for Viking Therapeutics (VKTX) over the last 6 years, with Sep 2025 value amounting to $10,000.
- Viking Therapeutics' Gains from Investment Securities fell 99.79% to $10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $250,000, marking a year-over-year decrease of 94.86%. This contributed to the annual value of $4.7 million for FY2024, which is 9.80% down from last year.
- Per Viking Therapeutics' latest filing, its Gains from Investment Securities stood at $10,000 for Q3 2025, which was up 150.00% from $4,000 recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Gains from Investment Securities registered a high of $5.8 million during Q1 2023, and its lowest value of $2,000 during Q2 2024.
- For the 3-year period, Viking Therapeutics' Gains from Investment Securities averaged around $3.0 million, with its median value being $4.9 million (2024).
- In the last 5 years, Viking Therapeutics' Gains from Investment Securities spiked by 972.54% in 2022 and then slumped by 99.96% in 2024.
- Quarterly analysis of 5 years shows Viking Therapeutics' Gains from Investment Securities stood at $234,000 in 2021, then soared by 972.54% to $5.1 million in 2022, then increased by 13.58% to $5.2 million in 2023, then slumped by 99.96% to $4.9 million in 2024, then slumped by 99.79% to $10,000 in 2025.
- Its Gains from Investment Securities was $10,000 in Q3 2025, compared to $4,000 in Q2 2025 and $4.9 million in Q3 2024.